Physicians' Academy for Cardiovascular Education

HDL as a risk marker and as a treatment target?

3' education - Nov. 1, 2011

HDL as a risk marker and as a treatment target?

Prof. Ulf Landmesser, Zurich and prof. John Deanfield, London are talking about good and bad cholesterol; HDL being the good cholesterol for years to the public. HDL might not always be good cholesterol. A big distinction has to be made between using HDL as a risk marker and as a treatment target; HDL cholesterol alone cannot be the treatment target. Each HDL targeted therapy has to be very carefully looked at.

It has to be investigated how to improve the anti-atherogenic functions of HDL. The HDL metabolism is very complex; the correct target within that metabolism has to be identified. HDL thus becomes very important as a new form of treatment compared to just lowering LDL cholesterol with statins.

Topics discussed in this PACE talk:

  • Why is HDL not always the good cholesterol?
  • CETP as HDL-targeted therapy – is it safe?
  • What did you see in patients with coronary artery disease?
  • Is raising HDL always beneficial? 
  • What is the most important information from dal-VESSEL?

View the slides

Share this page with your colleagues and friends: